MCIM
AMRX icon

Meadow Creek Investment Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Meadow Creek Investment Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-5,456
Closed -$89K – 1317
2018
Q2 		$89K Buy
+5,456
New +$95.8K ﹤0.01% 1215

Other funds holding AMRX

FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Meadow Creek Investment Management's AMRX Position: Q3 2018 in Review

Meadow Creek Investment Management sold out of Amneal Pharmaceuticals (AMRX) in Q3 2018, closing a stake of 5,456 shares — an estimated $89K sold.

Meadow Creek Investment Management first reported a position in AMRX in Q2 2018 and held it in 1 quarter. The position peaked at $89K in Q2 2018. 167 funds tracked by Wall St. Rank hold AMRX as of Q3 2018.

  • Meadow Creek Investment Management reported no remaining Amneal Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Meadow Creek Investment Management sold 5,456 Amneal Pharmaceuticals shares in Q3 2018, an estimated $89K.
  • Meadow Creek Investment Management first reported a position in Amneal Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Meadow Creek Investment Management's Amneal Pharmaceuticals position peaked at $89K in Q2 2018.
  • 167 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2018.

Based on Meadow Creek Investment Management's 13F filing for Q3 2018, filed 14 Nov 2018.